Ovid Therapeutics Inc. Aktie News

Ovid Therapeutics Inc. - Special Call Company Participants Victoria Fort - Senior Vice President of Corporate Affairs & Corporate Strategy Jeremy Levin - CEO & Chairman Meg Alexander - President & COO Conference Call Participants Laura Chico - Wedbush Securities Inc., Research Division Ritu Baral - TD Cowen, Research Division Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division...

Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrants Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exe...

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced positive topline results from its Phase 1 healthy volunteer study evaluating the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) activity of OV329, a n...

Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025 $7.0 million royalty monetization agreement signed with Immedica Pharma AB for future ganaxolone royalties, delivering capital to the Company from a non-pipeline asset OV4071, the first ever oral KCC2 direct activator, is completing an IND-enabling package; Ovid anticipates f...

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, announced today that the Company's management will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025. About Ovid Therapeutics Ovid Therapeutics Inc. ...

Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP costs Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP costs

Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid's first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-end Cash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expec...